


A mechanism for the reaction is proposed based on a report of *Takikawa et al.* [9] (*Scheme 2*). It seems that the bromo(dimethyl)sulfonium ion (**5**), formed by reaction of DMSO with **2**, is the active intermediate in the reaction. Meanwhile, benzothioamide **1** undergoes an *S*-bromination with this reactive intermediate to produce, after loss of Me₂S, **6**, which, after releasing HBr and sulfur affords the *S*-brominated compound **7**. Finally, this undergoes intermediate cyclization to the corresponding 3,5-diaryl-1,2,4-thiadiazole **3**, alongside elimination of HBr.

Scheme 2



As shown, DMSO has a vital function in the course of the reaction because it plays the role as reagent and solvent. The proposed mechanism was supported by isolation of mandelonitrile as by-product. Fortunately, mandelonitrile was soluble in the reaction media, and the corresponding thiadiazole precipitated as fine crystals. To isolate the pure product, cold MeOH was added, and the mixture was filtered. Compounds **2** with three differently substituted phenyl groups were reacted with benzothioamide **1** to assess the effect of the substituents on the course of the reaction. The results are compiled in *Table 1*.

Six different benzothioamide derivatives, **1a–1f**, were probed to evaluate the scope of this new synthetic approach. The results are collected in *Table 2*.

Unexpectedly, a different result was obtained, when the reaction of 4-chlorobenzenecarbothioamide (**1g**) with 2-bromo-2-phenylacetonitrile (**2a**) was carried out in a small amount of DMF as solvent. In this case, the reaction proceeded at room temperature leading to 2-(4-chlorophenyl)-5-phenyl-1,3-thiazol-4-amine (**8a**) as the major product (84% yield). As shown in the mechanism proposed in *Scheme 3*, formation of compound **8a** can be attributed to a different pathway followed under this condition.

Conclusions. – In summary, an unexpected result of the reaction of benzothioamide derivatives with 2-bromo-2-phenylacetonitrile in different solvents was observed. The novel reaction could be successfully employed for the mild, rapid, and efficient conversion of benzothioamide derivatives to the corresponding thiadiazoles or thiazol-

Table 1. Preparation of Compound **3a** from **1a** and **2a–2c**.

Entry	2	Ar	Solvent	Yield ^{a)} [%]
1	2a	Ph	DMSO	90
2	2a	Ph	Dioxane	16
3	2b	4-Cl-C ₆ H ₄	DMSO	88
4	2b	4-Cl-C ₆ H ₄	Dioxane	17
5	2c	4-NO ₂ -C ₆ H ₄	DMSO	80
6	2c	4-NO ₂ -C ₆ H ₄	Dioxane	12

^{a)} Pure isolated products.


Table 2. Oxidative Cyclization of Benzothioamides Using 2-Bromo-2-phenylacetonitrile (**2a**)

Entry	Ar	1	Time [min]	Product 3 ^{a)}	Yield ^{b)} [%]
1	3-Br-C ₆ H ₄	1a	6	3a	90
2	4-Br-C ₆ H ₄	1b	6	3b	90
3	2-Cl-C ₆ H ₄	1c	8	3c	88
4	3-Cl-C ₆ H ₄	1d	7	3d	89
5	4-F-C ₆ H ₄	1e	8	3e	83
6	2,4-Cl ₂ -C ₆ H ₃	1f	8	3f	85

^{a)} All products were characterized by ¹H- and ¹³C-NMR spectroscopy. ^{b)} All yields refer to pure isolated products.

4-amines depending on the choice of solvent. The significance of the presented method lies in the simplicity of performing the reaction and the isolation of the product. To the best of our knowledge, the method also seems to be one of the simplest and the fastest routes for the preparation of 3,5-diaryl-1,2,4-thiadiazoles and/or 2,5-diarylthiazol-4-amines so far investigated.

Scheme 3



Experimental Part

General. All solvents were dried and distilled before use according to standard procedures. M.p.: in sealed capillaries; uncorrected. Anal. TLC: silica gel (SiO₂; Merck 60 F₂₅₄) coated on aluminum plates; visualization by UV and with aq. KMnO₄ soln. IR Spectra: UR-20 spectrometer; KBr pellets; $\tilde{\nu}$ in cm⁻¹. ¹H- and ¹³C-NMR spectra in CDCl₃ and (D₆)DMSO on Bruker AMX-500 spectrometers; δ in ppm rel. to Me₄Si as internal standard, *J* in Hz.

Caution: All experiments should be carried out in an efficient hood to avoid exposure to very unpleasant Me₂S vapors. All 2-bromo-2-phenylacetonitriles are highly lachrymatory, and skin-irritant compounds should be handled with great care.

General Procedure for the Preparation of 2-Bromo-2-phenylacetonitriles 2. In a 100-ml round-bottom flask, phenylacetonitrile derivative (50 mmol) in dry toluene (50 ml) was dissolved and heated to 90°. Thereafter, Br₂ (52 mmol, 8.32 g, 2.67 ml) was added dropwise during 20 min with vigorous stirring. Heating was continued for a further 40 min. Then, the mixture was cooled to r.t., washed with NaHCO₃ soln. (5%, 2 × 25 ml), and then with H₂O (2 × 50 ml). The org. phase was dried (MgSO₄), and the solvent was removed under reduced pressure to obtain the 2-bromo-2-phenylacetonitrile derivative.

General Procedure for the Preparation of 3,5-Diaryl-1,2,4-thiadiazoles 3a–3e. Benzothioamide **1** (3 mmol) and **2** (1.5 mmol) was dissolved in DMSO (1 ml) and heated at 60° for the times noted in Table 2. After completion of the reaction (TLC) and cooling to ambient temp., the mixture was poured into MeOH/H₂O 85:15 (4 ml), and the resulting crystals of the product were filtered, washed with MeOH/H₂O 1:1 (2 × 5 ml), and dried to obtain pure compound as white crystals.

General Procedure for the Preparation of 2,5-Diarylthiazol-4-amines 8. Benzothioamide **1** (3 mmol) and **2** (3 mmol) were dissolved in DMF (1 ml) and stirred at r.t. for 20 min. Thereafter, the mixture was poured into H₂O (5 ml), and the crude precipitated product was filtered. The product was purified by crystallization from AcOEt/Et₂O to afford compound **8** as deep yellow crystals.

3,5-Bis(3-bromophenyl)-1,2,4-thiadiazole (3a). Yield: 533 mg (90%). White crystals. IR: 2941, 2857, 1581, 763. ¹H-NMR: 8.51 (s, 1 H); 8.32 (d, *J* = 8.7, 1 H); 8.21 (s, 1 H); 7.93 (dd, *J* = 8.4, 1.5, 1 H); 7.68 (ddd, *J* = 8.4, 1.5, 0.8, 1 H); 7.60–7.68 (m, 2 H); 7.35–7.42 (m, 2 H). ¹³C-NMR: 186.8; 172.4; 134.9; 134.5; 133.4; 130.8; 130.3; 126.9; 126.1; 123.4; 122.9. Anal. calc. for C₁₄H₈Br₂N₂S (396.10): C 42.45, H 2.04, N 7.07, S 8.10; found: C 42.28, H 1.99, N 7.15, S 8.31.

3,5-Bis(4-bromophenyl)-1,2,4-thiadiazole (3b). Yield: 534 mg (90%). White crystals. IR: 2985, 2843, 1593, 775. ¹H-NMR: 8.24 (d, *J* = 8.5, 2 H); 7.90 (d, *J* = 8.5, 2 H); 7.66 (d, *J* = 6.9, 2 H); 6.64 (d, *J* = 6.9,

2 H). ^{13}C -NMR: 187.2; 172.9; 132.8; 131.6; 129.8; 129.5; 128.8; 126.6; 125.1. Anal. calc. for $\text{C}_{14}\text{H}_8\text{Br}_2\text{N}_2\text{S}$ (396.10): C 42.45, H 2.04, N 7.07, S 8.10; found: C 42.30, H 2.01, N 7.10, S 8.25.

3,5-Bis(2-chlorophenyl)-1,2,4-thiadiazole (3c). Yield: 404 mg (88%). White crystals. IR: 2976, 2854, 1580, 784. ^1H -NMR: 7.40–7.42 (m, 2 H); 7.46–7.48 (m, 2 H); 7.55–7.60 (m, 2 H); 8.05 (td, $J = 7.2, 2.2, 1$ H); 8.65 (td, $J = 7.2, 2.1, 1$ H). ^{13}C -NMR: 126.8; 127.5; 129.6; 130.7; 130.8; 130.9; 132.1; 132.3; 133.3; 133.8; 173.2; 183.1. Anal. calc. for $\text{C}_{14}\text{H}_8\text{Cl}_2\text{N}_2\text{S}$ (307.20): C 54.74, H 2.62, N 9.12, S 10.44; found: C 54.51, H 2.45, N 9.05, S 10.55.

3,5-Bis(3-chlorophenyl)-1,2,4-thiadiazole (3d). Yield: 410 mg (89%). White crystals. IR: 2995, 2813, 1590, 751. ^1H -NMR: 7.43–7.49 (m, 3 H); 7.52–7.54 (m, 1 H); 7.90 (d, $J = 7.6, 1$ H); 8.07 (s, 1 H); 8.27 (d, $J = 7.0, 1$ H); 8.39 (s, 1 H). ^{13}C -NMR: 125.7; 126.4; 127.3; 128.5; 130.0; 130.6; 132.0; 132.1; 134.3; 134.8; 135.5; 172.5; 186.9; Anal. calc. for $\text{C}_{14}\text{H}_8\text{Cl}_2\text{N}_2\text{S}$ (307.20): C 54.74, H 2.62, N 9.12, S 10.44; found: C 54.60, H 2.51, N 9.10, S 10.61.

3,5-Bis(4-fluorophenyl)-1,2,4-thiadiazole (3e). Yield: 341 mg (83%). White crystals. IR: 2998, 2855, 1602, 771. ^1H -NMR: 7.16–7.24 (m, 4 H); 8.05 (ddd, $J = 11.9, 5.2, 2.8, 2$ H); 8.38 (ddd, $J = 12.2, 6.7, 3.3, 2$ H). ^{13}C -NMR: 115.7; 116.5; 129.6; 130.4; 163.2; 163.9; 165.2; 166.0; 172.8; 187.0. Anal. calc. for $\text{C}_{14}\text{H}_8\text{F}_2\text{N}_2\text{S}$ (274.29): C 61.30, H 2.94, N 10.21, S 11.69; found: C 61.21, H 2.80, N 10.02, S 11.80.

3,5-Bis(2,4-dichlorophenyl)-1,2,4-thiadiazole (3f). Yield: 478 mg (85%). White needles. IR: 2971, 2839, 1597, 769. ^1H -NMR: 7.40 (dd, $J = 8.4, 2.1, 1$ H); 7.47 (dd, $J = 8.7, 2.1, 1$ H); 7.58 (d, $J = 2.1, 1$ H); 7.62 (d, $J = 2.1, 1$ H); 8.04 (d, $J = 8.4, 1$ H); 8.57 (d, $J = 8.7, 1$ H). ^{13}C -NMR: 120.7; 127.2; 128.1; 130.3; 130.8; 131.4; 133.1; 134.2; 134.4; 136.3; 136.4; 138.0; 173.2; 182.3. Anal. calc. for $\text{C}_{14}\text{H}_6\text{Cl}_4\text{N}_2\text{S}$ (376.09): C 44.71, H 1.61, Cl 37.71, N 7.45, S 8.53; found: C 44.60, H 1.54, N 7.37, S 8.74.

2-(4-Chlorophenyl)-5-phenyl-1,3-thiazol-4-amine (8a). Yield: 695 mg (81%). Yellow crystals. IR: 3330, 3276, 3039, 1615, 825. ^1H -NMR (400 MHz, $(\text{D}_6)\text{DMSO}$): 7.85–7.87 (d, $J = 8.4, 2$ H); 7.53–7.55 (m, 4 H); 7.38–7.42 (t, $J = 7.6, 2$ H); 7.20–7.24 (t, $J = 7.6, 1$ H); 5.80 (s, 2 H). ^{13}C -NMR (100 MHz, $(\text{D}_6)\text{DMSO}$): 160.5; 154.3; 134.8; 132.8; 132.3; 129.7; 129.5; 127.4; 126.3; 126.1; 106.1. Anal. calc. for $\text{C}_{15}\text{H}_{11}\text{ClN}_2\text{S}$ (286.78): C 62.82, H 3.87, N 9.77, S 11.18; found: C 62.59, H 4.10, N 9.43, S 10.90.

5-(4-Chlorophenyl)-2-phenyl-1,3-thiazol-4-amine (8b). Yield: 720 mg (84%). Yellow crystals. IR: 3337, 3265, 3052, 1617, 761. ^1H -NMR (400 MHz, $(\text{D}_6)\text{DMSO}$): 7.85–7.87 (m, 2 H); 7.54–7.57 (m, 2 H); 7.45–7.50 (m, 5 H); 4.42 (s, 2 H). ^{13}C -NMR (100 MHz, $(\text{D}_6)\text{DMSO}$): 132.8; 132.3; 131.1; 129.8; 129.7; 129.5; 129.3; 128.0; 126.1. Anal. calc. for $\text{C}_{15}\text{H}_{11}\text{ClN}_2\text{S}$ (286.78): C 62.82, H 3.87, N 9.77, S 11.18; found: C 62.48, H 3.99, N 9.55, S 10.81.

2,5-Bis(4-chlorophenyl)-1,3-thiazol-4-amine (8c). Yield: 700 mg (73%). Yellow crystals. IR: 3424, 3341, 3018, 1596, 754. ^1H -NMR (400 MHz, $(\text{D}_6)\text{DMSO}$): 7.86–7.88 (d, $J = 8.4, 2$ H); 7.54–7.57 (m, 4 H); 7.45–7.48 (d, $J = 8.4, 2$ H); 6.62 (s, 2 H). ^{13}C -NMR (100 MHz, $(\text{D}_6)\text{DMSO}$): 162.3; 147.5; 135.5; 132.5; 131.6; 130.3; 129.9; 129.6; 129.5; 127.7; 114.2; Anal. calc. for $\text{C}_{15}\text{H}_{10}\text{Cl}_2\text{N}_2\text{S}$ (321.22): C 56.09, H 3.14, N 8.72, S 9.98; found: C 55.89, H 3.36, N 9.43, S 10.90.

We are grateful to the Research Council of the University of Isfahan for financial support.

REFERENCES

- [1] T. S. Jagodziński, *Chem. Rev.* **2003**, *103*, 197.
- [2] O. A. Attanasi, L. De Crescentini, E. Foresti, R. Galarini, S. Santeusano, F. Serra-Zanetti, *Synthesis* **1995**, 1397; A. Lorente, J. L. Garcia Navio, L. Fuentes, J. L. Soto, *Synthesis* **1985**, 86; K. Bogdanowicz-Szwed, J. Grochowski, A. Obara, B. Rys, P. Serda, *J. Org. Chem.* **2001**, *66*, 7205.
- [3] A. R. Katritzky, W.-Q. Fan, *J. Heterocycl. Chem.* **1993**, *30*, 1679; J. Gasteiger, C. Herzig, *Tetrahedron* **1981**, *37*, 2607.
- [4] E. A. Mamaeva, A. A. Bakibaev, *Tetrahedron* **2003**, *59*, 7521.
- [5] M. W. Cronyn, T. W. Nakagawa, *J. Am. Chem. Soc.* **1952**, *74*, 3693.
- [6] J. R. Cashman, R. P. Hanzlik, *J. Org. Chem.* **1982**, *47*, 4645.
- [7] A. Castro, T. Castaño, A. Encinas, W. Porcal, C. Gil, *Bioorg. Med. Chem.* **2006**, *14*, 1644.
- [8] U. Miotti, *J. Chem. Soc., Perkin Trans. 2* **1991**, 617.
- [9] Y. Takikawa, K. Shimada, K. Sato, S. Sato, S. Takizawa, *Bull. Chem. Soc. Jpn.* **1985**, *58*, 995.

- [10] R. Leung-Toung, T. F. Tam, J. M. Wodzinska, Y. Zhao, J. Lowrie, C. D. Simpson, K. Karimian, M. Spino, *J. Med. Chem.* **2005**, 48, 2266.
- [11] P. C. Unangst, G. P. Shrum, D. T. Connor, R. D. Dyer, D. J. Schrier, *J. Med. Chem.* **1992**, 35, 3691.
- [12] A. M. Macleod, R. Baker, S. B. Freedman, S. Patel, K. J. Merchant, M. Roe, J. Saunders, *J. Med. Chem.* **1990**, 33, 2052.
- [13] R. Leung-Toung, T. F. Tam, Y. Zhao, C. D. Simpson, W. Li, D. Desilets, K. Karimian, *J. Org. Chem.* **2005**, 70, 6230.
- [14] F. Matloubi Moghaddam, H. Zali Boeini, *Synlett* **2005**, 1612; F. Matloubi Moghaddam, H. Zali Boeini, *Tetrahedron* **2004**, 60, 6085; F. Matloubi Moghaddam, H. Zali Boeini, *Tetrahedron Lett.* **2003**, 44, 6253.

Received March 15, 2011